ADR Biomedical Holdings (TSE:3750) EBITDA Margin %: -798.35% (As of Mar. 2026)


TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円805.00
GF Value 円40.42
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings EBITDA Margin %?

ADR Biomedical Holdings TSE:3750 -1.23% 30 EBITDA Margin % is -798.35% as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 936 Biotechnology companies, ADR Biomedical Holdings ranks worse than 76.82% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ADR Biomedical Holdings's EBITDA for the six months ended in Mar. 2026 was 円-261.12 Mil. ADR Biomedical Holdings's Revenue for the six months ended in Mar. 2026 was 円32.71 Mil. Therefore, ADR Biomedical Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was -798.35%.


ADR Biomedical Holdings  (TSE:3750) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ADR Biomedical Holdings EBITDA Margin % Related Terms


ADR Biomedical Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings EBITDA Margin % Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.12 -32.89 -38.65 -1,653.95 -742.68

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.02 -402.15 -5,373.56 -643.07 -798.35

TSE:3750 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, ADR Biomedical Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADR Biomedical Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ADR Biomedical Holdings's EBITDA Margin % falls into.


TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ADR Biomedical Holdings's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-378.677/50.988
=-742.68 %

ADR Biomedical Holdings's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-261.123/32.708
=-798.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -798.35% mean?
ADR Biomedical Holdings (TSE:3750) has a EBITDA Margin % of -798.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #719 out of 936 companies in the Biotechnology industry, placing it in the top 76.8%.
Is ADR Biomedical Holdings' EBITDA Margin % too high?
ADR Biomedical Holdings' current EBITDA Margin % is -798.35%. Based on the distribution chart, ADR Biomedical Holdings ranks #719 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #719 out of 936 companies for EBITDA Margin %. This places ADR Biomedical Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current EBITDA Margin % is -798.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current EBITDA Margin % is -798.35%. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current EBITDA Margin % is -798.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • EBITDA Margin %: -798.35%
  • GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円805.00
Price
円40.42
GF Value